Press release

Siemens Healthineers adds pathway for lung cancer to its AI-based clinical decision support software

HIMSS 2021, Las Vegas, August 9-13, 2021

Published on August 9, 2021
<p></p><ul><li><b>New AI solution enables personalized decision making along the lung cancer pathway</b></li><li><b>Facilitates patient management and case reviews by combining into a single dashboard</b></li><li><b>Second pathway for AI-Pathway Companion after pathway for prostate cancer</b></li></ul><p></p> <p>Siemens Healthineers presents its second pathway for its AI-Pathway Companion<sup>1</sup> at the Healthcare Information and Management Systems Society Global Health Conference 2021 (HIMSS 21). This new pathway is focused on non-small cell lung cancer, supporting personalized and standardized decision-making along the whole treatment process<sup>2</sup>. The AI-Pathway Companion Lung Cancer<sup>3</sup> assists multidisciplinary teams (MDT) by facilitating patient management and case reviews in a single dashboard, providing quality checks on data completeness, and enabling the documentation of clinically relevant patient-specific notations. “During lung MDT discussion, it frequently becomes apparent that a key diagnostic report or other crucial information is not yet available. These patients have to be discussed again in the next meeting. This wastes time and effort for all physicians involved in the MDT. A digital assistant, which ensures that the right set of information is available, would substantially increase efficiency”, says Prof. Mathias Prokop, Head of the department Radiology, Nuclear Medicine and Anatomy, Radboud University Nijmegen<sup>4</sup>.</p> <p><b>AI-Pathway Companion</b></p> <p>Siemens Healthineers adds the pathway for lung cancer for its AI-Pathway Companion to the already existing CE-marked pathway for prostate cancer. The software is designed to help in advanced oncology care by integrating contextualized data along the patient pathway. Utilizing the full pathway with all available data<sup>2</sup>, healthcare professionals can optimize the treatment for the individual patient and adherence to evidence-based standards of care is easier to accomplish<sup>5</sup>. This transparency also helps collaboration across departments and cancer boards. Everyone involved always has the full picture and can contribute to the treatment discussion with their specific knowledge. “The introduction of the AI-Pathway Companion Lung Cancer demonstrates our continued commitment to supporting healthcare providers in their transformation to value-based healthcare. With the AI-Pathway Companion solution, we are presenting a next-gen clinical decision support system; we want to continue trail blazing in this market by partnering with key customers on future innovation”, says Wido Menhardt, Head of Digital Health at Siemens Healthineers.</p> <p>Through ongoing development and refinement of data interfaces, Siemens Healthineers aims to increase the number of disease parameters captured throughout the clinical pathway, thereby expanding the relevant data points with the goal of advancing cancer care. The company looks forward to partnering with even more healthcare institutions on optimizing the AI-Pathway Companion solution to their routine clinical practice and preferred lung cancer workflow.</p>

Download image


Siemens Healthineers 2021

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide. Further information is available at